Bethanie Wilkinson

6.5k citations

36 papers · 3.7k indexed · 2 hit papers · h-index 22

Impact in

Rheumatology top 0.2%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research

Papers in

Rheumatology 27
- Rheumatoid Arthritis Research and Therapies 27
- Systemic Lupus Erythematosus Research 12
Hematology 16
- Autoimmune and Inflammatory Disorders Research 16

Co-authors: Samuel H. Zwillich David Gruben Sriram Krishnaswami Gene V. Wallenstein Eun Bong Lee Roy Fleischmann Tamás Koncz Ronald van Vollenhoven
Journals: Annals of the Rheumatic Diseases (10 papers)The Journal of Infectious Diseases (4 papers)Vaccine (3 papers)Arthritis Research & Therapy (3 papers)RMD Open (3 papers)
Partner nations: United States South Korea Netherlands

In The Last Decade

Bethanie Wilkinson

35 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

Tofacitinib versus Methotrexate in Rheumatoid Arthritis 2014 · 598 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 New England Journal of Medicine
2012 New England Journal of Medicine

Peers

Countries citing papers authored by Bethanie Wilkinson

Since Specialization

Citations

This map shows the geographic impact of Bethanie Wilkinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bethanie Wilkinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bethanie Wilkinson more than expected).

Fields of papers citing papers by Bethanie Wilkinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bethanie Wilkinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bethanie Wilkinson. The network helps show where Bethanie Wilkinson may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Bethanie Wilkinson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bethanie Wilkinson Line = papers co-authored together Bethanie Wilkinson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses Vaccine ·Bethanie Wilkinson, V Carnicelli, Katherine R. Smith, Robert Walker, 엄세욱, Xiuting Zou, Gale Smith, Emily Smith, Marc Gurwith, Robert T. Chen	2023	2
2	Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis Arthritis Research & Therapy ·Philip G. Conaghan, Mikkel Østergaard, O. Troum, M.A. Bowes, Gwenael Guillard, Bethanie Wilkinson, Zhiyong Xie, John S. Andrews, Joshua Epstein, Douglass Chapman, Andrew Koenig	2019	21
3	Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials Clinical Rheumatology ·Vibeke Strand, Eun Bong Lee, Yusuf Yazıcı, Ara Dikranian, Bethanie Wilkinson, Liza Takiya, Chuanbo Zang, Eustratios Bananis, Martin Bergman	2018	7
4	Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6 Arthritis Care & Research ·Ronald van Vollenhoven, Eun Bong Lee, Lara Fallon, Samuel H. Zwillich, Bethanie Wilkinson, Douglass Chapman, Ryan DeMasi, Edward Keystone	2018	8
5	Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques Annals of the Rheumatic Diseases ·Philip G. Conaghan, Mikkel Østergaard, M.A. Bowes, Chun‐Ying Wu, Thomas Fuerst, Désirée van der Heijde, Fedra Irazoque-Palazuelos, 李佳隆, Paweł Hrycaj, Zhiyong Xie, Richard Zhang, Bradley T. Wyman, John Bradley, Koshika Soma, Bethanie Wilkinson	2016	85
6	Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials Arthritis Research & Therapy ·Robert Landewé, Carol A. Connell, John Bradley, Bethanie Wilkinson, David Gruben, Sander Strengholt, Désirée van der Heijde	2016	24
7	Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis Arthritis Research & Therapy ·Mark C. Genovese, Ronald van Vollenhoven, Bethanie Wilkinson, Lisy Wang, Samuel H. Zwillich, David Gruben, Pinaki Biswas, Richard J. Riese, Liza Takiya, Thomas V. Jones	2016	15
8	The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis Annals of the Rheumatic Diseases ·Kevin Winthrop, Joel C. Silverfield, Lucas Lins Vieira, Jeffrey Neal, Eun Bong Lee, Paweł Hrycaj, Juan J. Gómez‐Reino, Koshika Soma, Charles A. Mebus, Bethanie Wilkinson, Jennifer Hodge, Haiyun Fan, Tao Wang, Clifton O. Bingham	2015	141
9	Tofacitinib versus Methotrexate in Rheumatoid Arthritis New England Journal of Medicine ·Eun Bong Lee, Roy Fleischmann, Stephen Hall, Bethanie Wilkinson, John Bradley, David Gruben, Tamás Koncz, Sriram Krishnaswami, Gene V. Wallenstein, Chuanbo Zang, Samuel H. Zwillich, Ronald van Vollenhoven Hit paper breakdown →	2014	598
10	Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis New England Journal of Medicine ·Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, LI Rui-xing, 嘉穎稲浦, Šárka Forejtová, Samuel H. Zwillich, David Gruben, Tamás Koncz, Gene V. Wallenstein, Sriram Krishnaswami, John Bradley, Bethanie Wilkinson Hit paper breakdown →	2012	739
11	Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs Arthritis & Rheumatism ·Roy Fleischmann, Maurizio Cutolo, Mark C. Genovese, Eun Bong Lee, Keith S. Kanik, Seth Sadis, Carol A. Connell, David Gruben, Sriram Krishnaswami, Gene V. Wallenstein, Bethanie Wilkinson, Samuel H. Zwillich	2011	315
12	A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Arthritis & Rheumatism ·Joel M. Kremer, Stanley Cohen, Bethanie Wilkinson, Carol A. Connell, Jonathan French, Juan J. Gómez‐Reino, David Gruben, Keith S. Kanik, Sriram Krishnaswami, Virginia Pascual‐Ramos, Gene V. Wallenstein, Samuel H. Zwillich	2011	284
13	Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial Annals of the Rheumatic Diseases ·John Coombs, Bradley J. Bloom, F. C. Breedveld, Mark P. Fletcher, David Gruben, Joel M. Kremer, R Burgos-Vargas, Bethanie Wilkinson, Cristiano A. F. Zerbini, Samuel H. Zwillich	2009	116
14	Co‐administration of the JAK inhibitor CP‐690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment British Journal of Clinical Pharmacology ·Stanley Cohen, Samuel H. Zwillich, Vincent Chow, Robert R. LaBadie, Bethanie Wilkinson	2009	38
15	Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans Vaccine ·John J. Treanor, Bethanie Wilkinson, Z Chen, Jean Hu‐Primmer, Costanza Morbidelli, Diane O’Brien, Mark Wolff, 杉内由佳, William Blackwelder, Jacqueline M. Katz	2001	283
16	Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes Vaccine ·John M. Crawford, Bethanie Wilkinson, C. Zanotti, Gale Smith, Maricarmen Garcı́a, H. D. Stone, Michael L. Perdue	1999	106
17	Humoral and Cellular Immune Responses following Vaccination with Purified Recombinant Hemagglutinin from Influenza A (H3N2) Virus The Journal of Infectious Diseases ·Douglas C. Powers, Janet E. McElhaney, Anish Shah, Derek Graebel, Pascale Poulet-Coulibando, David W. Bentley, Bethanie Wilkinson	1997	37
18	Recombinant Baculovirus Influenza A Hemagglutinin Vaccines Are Well Tolerated and Immunogenic in Healthy Adults The Journal of Infectious Diseases ·David Lakey, John J. Treanor, Robert F. Betts, Gale Smith, Joshua J. Thompson, Edith C. Sannella, George Reed, Bethanie Wilkinson, Peter F. Wright	1996	58
19	Evaluation of a Recombinant Hemagglutinin Expressed in Insect Cells as an Influenza Vaccine in Young and Elderly Adults The Journal of Infectious Diseases ·John J. Treanor, Robert F. Betts, Gale Smith, E. L. Anderson, Christopher S. Hackett, Bethanie Wilkinson, Robert B. Belshe, Douglas C. Powers	1996	64
20	Influenza A Virus Vaccines Containing Purified Recombinant H3 Hemagglutinin Are Well Tolerated and Induce Protective Immune Responses in Healthy Adults The Journal of Infectious Diseases ·Douglas C. Powers, Gale Smith, E. L. Anderson, Donald J. Kennedy, Christopher S. Hackett, Bethanie Wilkinson, P. Jimenez-Royo, Robert B. Belshe, John J. Treanor	1995	91

About Bethanie Wilkinson

Bethanie Wilkinson is a scholar working on Rheumatology, Hematology, Genetics, Pathology and Forensic Medicine and Immunology, having authored 36 papers that have together received 3.7k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (27 papers), Autoimmune and Inflammatory Disorders Research (16 papers), Systemic Lupus Erythematosus Research (12 papers), Chronic Lymphocytic Leukemia Research (6 papers), Influenza Virus Research Studies (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Viral Infectious Diseases and Gene Expression in Insects (4 papers) and Viral Infections and Immunology Research (3 papers). The work is most often cited by research in Rheumatology (2.2k citations), Hematology (1.2k citations), Genetics (715 citations), Immunology (890 citations) and Oncology (744 citations). Bethanie Wilkinson has collaborated with scholars based in United States, South Korea and Netherlands. Frequent co-authors include Samuel H. Zwillich, David Gruben, Sriram Krishnaswami, Gene V. Wallenstein, Eun Bong Lee, Roy Fleischmann, Tamás Koncz, Ronald van Vollenhoven, John Bradley and Stanley Cohen. Their work appears in journals such as Annals of the Rheumatic Diseases, The Journal of Infectious Diseases, Vaccine, Arthritis Research & Therapy and RMD Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact